Apellis Pharmaceuticals appoints Dr Robert Kim as CMO

pharmafile | August 8, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Apellis, CMO, GSK, Novartis, appointment 

Clinical stage complement immunotherapy company Apellis Pharmaceuticals has named its new chief medical officer as Dr Robert Kim. Kim’s primary remit will be guiding the company in optimising its drug development strategy.

Dr Kim brings 30 years of clinical experience in ophthalmology to the company, having previously served tenures at GSK, Novartis/Alcon, Zeiss Humphrey Systems (now Carl Zeiss Meditec) and Vision Medicines.

CEO of Apellis Pharmaceuticals Cedric Francois said of the appointment: “We are delighted to welcome Dr Kim to Apellis. Bob is an experienced clinical drug developer whose deep knowledge and experience will help us prepare for our confirmatory trials in geography atrophy and the further expansion of our exciting clinical pipeline centred on the inhibition of complement factor C3.”

Advertisement

Kim himself noted: “I am very excited to be joining Apellis, a trailblazer of new therapies for patients suffering from diseases arising from inappropriate activity of the complement system.”

Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Novartis receives SMC approval for early breast cancer treatment

Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

drug-trials

Novartis candidate for Sjögren’s disease presents positive results

Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

The Gateway to Local Adoption Series

Latest content